Collegium Pharmaceutical’s (COLL) Neutral Rating Reiterated at Piper Sandler
Piper Sandler reissued their neutral rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $37.00 target price on the specialty pharmaceutical company’s stock, up from their prior target price of $36.00. A number of other equities research analysts […]
Piper Sandler reissued their neutral rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $37.00 target price on the specialty pharmaceutical company’s stock, up from their prior target price of $36.00. A number of other equities research analysts […]
